September 8th, Grand Hotel, Stockholm, Sweden Event...

Event Guide

Medtech Investment Day Scandinavia 2011

Medtech Investment Day Scandinavia is co-presented by the Nordic associations for Medical Technology

Partners and Sponsors

Media Partner

September 8th, Grand Hotel, Stockholm, Sweden

Day Scandinavia 2011September 8th, Grand Hotel, Stockholm, Sweden

Medtech Investment

Presenting companies

AddBIO

Biomologic

Brighter

Cathprint

Chundsell

Doxa

Encare

EPiQ Lifescience

FAMSports

Healthy Life Devices

iDoc24

Isentio

Laprotech

Linkura

Medfield Diagnostics

Modz

Ostomycure

Relaxbirth

SenCere Medical

Setred

Swedish Operating Theatres

Valkee

Vivoline Medical

Volusense

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

16

17

18

19

20

21

22

23

24

25

26

27

AddBIO

Contact person: Trine Vikinge

Location: Linköping, Sweden

E-mail: [email protected]

Phone: +46 132 100 60

Web: www.addbio.se

AddBIO is developing Zolidd, a unique biomaterial enhancing the fixation of implants and screws by strengthening the bone surrounding them.

Implant loosening causes patient suffering and is a resource demanding problem, leading to high costs for patient care and reoperations. Compromised bone quality is a significant part of the problem, and improving the strength of the bone surrounding the implant therefore lowers the risk for loosening and other complications.

Zolidd is based on orthopedic surgeon Professor Aspenberg’s research. It is the first application of theFibMat technology, a proprietary platform for local drug availability from implants. Zolidd enables the bone strengthening drug bisphosphonate to be released locally, directly from the implant.

Zolidd is compatible with most types of orthopedic implants as it strengthens the bone without changing the underlying properties of the implant itself. Zolidd is aimed at trauma, spine, reconstructive orthope-dics and dental implants. The total orthopedic market is worth approximately 30 billion USD, out of which a large part is addressable by Zolidd. Efficacy has been shown in a dental clinical study. Two additional clinical studies are currently on-going, an extended dental study as well as an osteotomy study. Results are to be expected during fall 2011.

4

Biomologic

Contact person: Adam Hillestrøm

Location: Roskilde, Denmark


Phone: +45 213 266 65

Web: www.biomologic.dk

Biomologic Sensing will be spun out from The Technical University of Den-mark and will be launched during Q4 2011. The company will market a high throughput screening platform to be used in drug discovery.

With the use of Biomologics platform substantial savings in terms of time and money for development of new drugs can potentially be realized.The paradigm shifting technology enables label-free, free solu-tion measurements of biomolocolar intercations ranging from small molecule inhibitor studies to protein-protein bindings. Thereby realtime unperturbed binding kinetic information can be obtained. Over the long term Biomologic plans to develop the platform to be applied for diagnostic puposes as well given the unprecedented high sensitivity and level of quantification.

Biomologic is based on more than 10 years of research and the technology platform offers an overall best in clas performance compared with industry standard methods like ITC, Elisa and SPR. Biomologic is currently looking for an investment of approximately 1 million €, which will bring the company to its first instrument sale and positive cashflow.

A 5-year budget has been developed showing a total 5 year turnover of 65+ million € with 32+ million € in turnover in year 5, i.e. an exponential growth. Three exit strategies can be considered: Sale to an instrument manufacturer (competitor/partner) before launch of the diagnostic platform (1), after the value

of the diagnostic platform has been demonstrated (2) or IPO after launch of the diagnostic platform (3).

5

Brighter

Brighter develops and commercializes innovative solutions for diabetes self-cafe.

It is a STING Alumni company. Financing has come from state and institutional investors such as ALMI, Innovationsbron, KAS Innovationsfond (an activity within the Karl-Adam Bonnier foundation) as well as from private investors.During the period August 15 to September 26, there is a unique opportunity to issue shares in Brighter. After the introduction issuing, Brighter will be listed at AktieTorget. For more information: www.Brighter-Company.com. There are 1.3 million diabetics in Scandinavia. A significant share of diabetics needs to bring with them several products to manage their daily self care routine. Low compliance in use of these items can lead to serious complications such as kidney failure, blindness, neuropathy leading in worst case to amputa-tion. Brighter AB develops a unique integrated all-in-one solution that simplifies everyday life for diabetics

and improves self care.

Contact person: Truls Sjöstedt

Location: Stockholm, Sweden


Phone: +46 709 73 46 00

Web: www.brightercompany.com

Brighter

6

Cathprint

Contact person: Bengt Källbäck



Phone: +46 706 67 32 33 Web: www.cathprint.se

CathPrint AB offers a catheter design and manufacturing technology that will• rationalise existing catheters• realise challenging product concepts into marketable products, also

products that are impossible to manufacture with current technology• enabling significant cost savings, improved performance and increased

profitablity for catheter companies.

CathPrint will establish a production line and start production for it’s first two customers during 2011. A contract is signed with one of these companies and production establishment projects planned with both of them.Discussions are ongoing with several other potential customers, among them two large US companies.

Positive cash flow is expected during 2013 and by 2015 a turnover of 20 MSEK.The company is made attractive for takeover by a large catheter company or a large OEM supplier of catheters through - establishing our technology on the market by our first customers - strengthening our patent portfolio to protect the technology

Investment recquirements are 5-7 MSEK to be used to - strengthen the organization - establish a production line - complete certification of the company (ISO 13485) - start aggressive marketing and sales

CathPrint

7

Chundsell Medicals AB is a spin off company from Cancer Center Karolin-ska in Stockholm Sweden.

The company is in a phase where a 15 yeras R&D project about how to predict the agressivnes of prostate cancers can be turned into a diagnostic test, the ”Prostatype” avavilible for general and routine laboratories around the world.

A large and long ”end-point” study based on Real-Time PCR technology where the expression af a certain number of specfic genes can tell the urologist if and how nessesary it is to take surgery or other healing action on the patient or not.

The clinical decision taken will have important and long term consecuenses for the patients future Qua-lity of Life and and also have big impact on the general Health Economy for prostate cancer patients in general.

The results gained from the test can also lead to a specific and personalised medicine and teraphtical treatment for the specific patient.

The test will be CE marked and will have a commercial launche to the market within the next coming 18

Contact person:Jan Erik Collin



Phone: +46 705 67 15 81 Web: www.chundsell.com

Chundsell Medicals

Chundsell Medicals

8

Doxa is a Swedish-based company, developing, producing and marketing bioceramic dental products.

The first product, Ceramir® Crown & Bridge, is an advanced dental cement used for permanent fixture of dental crowns and bridges. The product was awarded the Frost & Sullivan “New Product Innovation Award 2010”

Ceramir Crown & Bridge was successfully launched in Sweden in November 2009. In January 2011 Doxa signed a global distribution agreement with Henry Schein, the world’s biggest dental distributor. Ceramir Crown & Bridge is launched by Henry Schein in US and Germany during second quarter 2011.

Ceramir Crown and Bridge is the first dental product in a range of products from Doxa based on the company’s technology platform Ceramir. Doxa has ongoing development projects and plans to launch one new product each year.

SLS Invest AB, Omega Fund, BGA Capital AB, Länsförsäkringsbolagen and the founder, Leif Hermans-son, are the company’s major shareholders. There are a further 1300 shareholders.

The company would like to raise a further 50 mSEK during the fall 2011.

Contact person: Fredrik Alpsten

Location: Uppsala, Sweden


Phone: +46 18 478 20 00 Web: www.doxa.se

Doxa

9

Encare provides ERAS® Care System, which supports centers performing major surgery to implement, support and maintain best practice – Enhan-ced Recovery After Surgery.

ERAS Care System is an evidence based protocol that improves quality and efficiency of perioperative care (The patients “journey” from admission to discharge). Studies from a number of centers show that ERAS radically reduces complications and length of stay.

ERAS Care System consists of three major parts; •ERAS Protocol – evidence based perioperative care protocol•ERAS Interactive Audit System (EIAS) – an internet-based data entry and analysis system•ERAS Implementation Program (EIP) – Surgeons, anesthesiologists and nurses are trained to work together for the best of the patient

The company is in early commercialization phase of the ERAS Care system. The ERAS Care Systemis presently running in a number of centers and a great number of new centers have confirmed their interest to get started. The business model is based on fixed fee for the ERAS Implementation Program and an-nual subscription fee for the ERAS Interactive Audit System.

Annual revenue growth of well above 100% for the period up to 2015 is planned. In 2010 the company received its first investment from Sting Capital of 2 mSEK. Encare is now seeking to raise another 2 mSEK. The proceeds will be used for the finalisation of certaion comoponents of the ERAS Care System and to start a broader rollout. The next financing round which will take the company to cash positive is scheduled for 2012/2013.

Contact person: Magnus Stafsin

Location: Kista, Sweden


Phone: +46 706 55 93 12 Web: www.encaregroup.com

Encare

10

EPiQ Life Science is devoted to finding innovative solutions for cardiology patients suffering from cardiac disease, e.g. atrial fibrillation (AF). EPiQ have developed a method for quantification of the seriousness of AF based on analysis of a standard ECG-recording.

By calculating parameters emanating from the electrical activity in the atria, most prominently atrial fibril-lation rate (AFR), it provides a new systematic approach for deciding on optimal treatment for patients with AF.

EpiQ will launch this method in two ways; one as a system for use in clinical practice, one as a web service for other systems to use. We anticipate that the second setting will enable us to grow into other business segments, like mobile health.

Currently, EPiQ have started product development and the company is now looking for an investment of €450 000. With these products launched, we expect a revenue growth to €3 500 000 within five years.

Contact person: Per Sundström



Phone: +46 736 55 92 71 Web: www.epiq.se

Epiq Life Science

11

HLD is medical device ISO 9001:2000/13485:2003 Certified Company. The mission of HLD is to alleviate physiotheprapy treatment indications in regard with lymphatic system, muscles, skin, neural tissue, joints and bones.

Examples of treatment indications are pre- and post-operative traumas, post-traumatic edemas, other selected edema indications, fibrotic tissue conditions, scar tissue conditions, open wound, sport injuries.

The mission will be fullfilled through developing, producing, and marketing high technology therapy de-vices, and related services, and through promoting the professionalism of the healthcare practitioners. The customers are healthcare practitioners, such as physical therapists, and other professionals working in hospitals, in therapy centers, and in patients’ homes. In addition to physiotherapy segment, HLD product solution is suitable for wellness and beauty market segment.

The product solution, LymphaTouch, is a new, patented, treatment concept for physiotherapy, wellness, sports recovery, and for the treatment of all the indications of manual lymphatic drainage therapy. Lymp-haTouch is CE marked as a medical device.

Investment Opportunity: Seeking Series A, 1M€. possible exit through trade sale in 2014-2015. Estimated LymphaTouch sales is 17 M€ in 2014.

Contact person: Tapani Taskinen

Location: Espoo, Finland


Phone: +35 850 544 84 44 Web: www.healthylifedevices.com

Healthy Life Devices

12

iDoc24 offers anonymous healthcare advice on any visual medical concern, anytime, anywhere, anyone, 24/7; using skin doctors. The service can be used through mobile telephones using Multimedia Mess-aging Service (MMS), mobile apps (iPhone & Android) or an Internet web form.

With a stressful every day life there is less time to handle unexpected health conditions. 80% of all pa-tients search their medical symptoms on the Internet prior to see a doctor, it is estimated that 15% of all general practitioner (GP) visits are skin related. If 50% of all skin related visits can be self-treated using our service, iDoc24 estimates a €200 million saving to the Swedish healthcare service. The EU and US market has 100 million and 60 million skin diseases respectively and the mHealth industry will be worth an estimated 5.7 billion dollars in 2015 the US alone .

Today the service is launched in the EU in Swedish, English and Spanish languages. We receive 3- 5 consultations a day, at a price of €10. We foresee that in the future each consultation will cost the user (patient) between €5-€10 and a reimbursement fee of €30-€50 from the customers (health services or insurance companies). There are further possible “kick back” models.

iDoc24 are expecting an exponential growth rate with the right investor and strategy, with 2 million cases per year in 2015 and a turnover of €50 million. We are seeking €500 000 to introduce the service to the US market in 2011. Possible exit is an IPO in 2015 or a sale to an industry interested in Healthcare (Mi-crosoft, Google, Mawell, General Electric Healthcare, Epocrates.com)

Contact person: Alexander Börve


E-maiil: [email protected]

Phone: +46 730 42 16 01 Web: www.iDoc24.com

iDoc24 offers anonymous healthcare advice on any visual medical con-cern, anytime, anywhere, anyone, 24/7; using skin doctors. The service can be used through mobile telephones using Multimedia Messaging Ser-vice (MMS), mobile apps (iPhone & Android) or an Internet web form.

With a stressful every day life there is less time to handle unexpected health conditions. 80% of all pa-tients search their medical symptoms on the Internet prior to see a doctor, it is estimated that 15% of all general practitioner (GP) visits are skin related. If 50% of all skin related visits can be self-treated using our service, iDoc24 estimates a €200 million saving to the Swedish healthcare service. The EU and US market has 100 million and 60 million skin diseases respectively and the mHealth industry will be worth an estimated 5.7 billion dollars in 2015 the US alone .

Today the service is launched in the EU in Swedish, English and Spanish languages. We receive 3- 5 consultations a day, at a price of €10. We foresee that in the future each consultation will cost the user (patient) between €5-€10 and a reimbursement fee of €30-€50 from the customers (health services or insurance companies). There are further possible “kick back” models.

iDoc24 are expecting an exponential growth rate with the right investor and strategy, with 2 million cases per year in 2015 and a turnover of €50 million. We are seeking €500 000 to introduce the service to the US market in 2011. Possible exit is an IPO in 2015 or a sale to an industry interested in Healthcare (Mi-crosoft, Google, Mawell, General Electric Healthcare, Epocrates.com)

Contact person: Alexander Börve



Phone: +46 730 42 16 01 Web: www.iDoc24.com

iDoc24

13

Isentio AS is developing software solutions for analysis and interpretation of complex sequencing data, with focus on clinical microbiology and iden-tification of infectious bacteria from single or mixed infections.

The unique software (patented) and database platform enables sequence-based identification directly from clinical samples or bacterial cultures, resulting in significant increase in diagnostic quality as well as time- and cost savings.

Target customers; universities, hospitals, laboratories with access to sequencing instrumentation. Cur-rent customers represent leading hospitals in Europe and USA. RipSeq Single; the low barrier entry-point which introduces RipSeq Mixed as a solution for more complex samples. Publications are availa-ble. RipSeq Single is covered by reimbursement in USA.

All products are web-based, no physical delivery or installations, with real-time search in proprietary or public databases which are constantly updated. Payment model; pre-payment for a chosen number of samples. Sales model; direct sales, distributors & co-marketing, use of on-line demos and trials.

The product platform has potential within human, veterinary, pharma, food & environment and is adap-table to future sequencing platforms. In Bergen & Silicon Valley, we host in-house research, software development, medical expertise and sales & marketing. We are searching an investment of € ca.3M to grow and capitalize on our market potential.

Contact person: Camilla Huse Bondesson

Location: Bergen, Norway


Phone: +46 706 66 82 09 Web: www.isentio.com

Isentio

14

FAM Sports is a non-invasive device to assess neuromuscular loading of athletes, to optimize training effect and recovery.

FAM Sports product concept is based on proprietary FAM assessment technology and it includes hard-ware and software components, the database of assessment results to be generated over time being the essential element of the future business.

In addition to sports, the clinically validated FAM assessment method is scalable to diagnostic use in primary healthcare and rehabilitation, or proving the efficacy physical therapy treatment.The first product version for professional sports is on the market and in test use of professional sports or-ganizations in Europe. Some distribution agreements have been made. The development of next product version for amateurs, i.e. all people who exercise goal-directedly, is to be started later this year.

The current investment need for the next five years is €3,3M.Turnover in 2015 is expected to be €29M, of which 2/3 come from professional product business and 1/3 from amateur product business. The bu-siness is expected to be profitable by 2014.

Exit possibilities include trade sale to either a sporting goods company or a diagnostic or electrotherapy device company. Sports and diagnostics businesses can also be sold separately to different industries.

Contact person: Katriina Otsamo

Location: Oulu, Finland


Phone: +35 844 551 30 05 Web: www.famsports.com

FAMSports

15

Laprotech AB has developed a laparoscopic suturing system that brings significant benefits to healtcare providers, surgeons, and patiens such that it reduces average suturing time with approximately 90%.

The inventor was recently awarded “Innovator of the year” in Västerås for his invention. The company has been presented in Dagens Industri on March 9.

The company is expecting regulatory approval in Q3 2011 and commercial launch in Q3 2011. The company is looking for a 5 MSEK equity injection to build production capacity and the commercial launch.

The company expects to achieve an installed base of 5,000 instruments within three years, with signi-ficant sales of single-use consumables. End user price for each system is expeced to vary between 15 and 25 KSEK. Several product extensions are in the pipe-line.

The company expects that both private placement or IPO are viable exit strategies.

Contact person: Lars-Johan Larsson

Location: Västerås, Sweden


Phone: +46 767 80 89 00 Web: www.laprotech.com

Laprotech

16

Linkura has developed a unique ecosystem of web and mobile services for people with diet related diseases that makes it easy to keep tabs on nutri-tional values and the effect of food on different physiological factors.

The nutrition services are offered for free together with subscription based plus services for specific diet related diseases, and a subscription based mobile offering.

The founders of Linkura make up a strong management team with complimentary development, ma-nagement and sales skills. The company is also supported by an active board of directors and medical advisory board.

Linkura has recently launched its first service, Linkura Diet, with already more than 1000 active users. Linkura is currently in the process of launching additional services, with subsequent launches in the english speaking markets. Turnover is expected to reach more than 100 msek 2015. Linkura is currently seed funded, and is currently planning a 2 msek financing round in the second half of 2011.

Contact person: Marcus Hultberg

Location: Linköping, Sweden


Phone: +46 707 77 32 24 Web: www.linkura.se

Linkura

17

Medfield will enable faster treatment for stroke victims by providing correct diagnosis at site, in the stroke unit and in the ambulance.

Faster diagnosis will allow emergency treatment and save millions of brain cells for stroke victims. This is possible with a compact device based on microwave technology and signal processing that detects changes in circulation and amount of blood inside the patients head. Acute diagnosis and treatment re-sults in substantially lower rehabilitation cost, where post-stroke rehabilitation is the largest cost builder in western healthcare.

Achievements:• Medfield’s first product Strokefinder R10 launched and sold to Sahlgrenska University Hospital• Clinical trial with 22 stroke patients finalized with positive results

Way to market:Medfield’s first product line Strokefinder R10 is sold to key opinion leaders at university hospitals to build credibility and documentation for the technology. First clinical product will solve the monitoring need for TIA-patients at stroke units who have a risk of getting a stroke during nighttime. Second clinical product will be sold to stroke units, emergency centers and ambulances for acute diagnosis and enable early treatment.

Financial strategy:Medfield will raise ~ 2 MEUR worth of equity. Exit is planned as trade sale or IPO within 4-5 years.

Contact person: Patrik Dahlqvist

Location: Gothenburg, Sweden


Phone: +46 317 41 17 53 Web: www.medfielddiagnostics.com

Medfield Diagnostics

18

Contact person: Pietari Päivänen

Location: Helsinki, Finland


Phone: +358 505 43 32 92 Web: www.bloomjack.com

Modz develops motivational devices and lifestyle solutions for smart-point-of-care. Modz’s first product to be commercialized is a unique diabetes ma-nagement system (DrModz) for type 1 and 2 diabetes care with integrated self-treatment software and real-time datatransfer to the care team.

Modz’s product is especially designed for children and juveniles. The other product is preventive exercise meter MyModz, with innovative approach to motivate children and elderly people to move more. My-Modz is a first-of-a-kind exercise motivator with a real social media and game approach. The company is currently negotiating with some of the world’s leading gaming companies about possible cooperation models.

MyModz is in its prototype 3 phase and it will be launched in fall 2011. DrModz is in its prototype 1 phase and it will be launched during the H1/2012.

Modz closed its first financing round of €1,2M in april 2011. The investments came from well known Finnish business angels and Tekes (the Finnish Funding Agency for Technology and Innovation). Pre-viously the company has been funded by e.g. Tekes / TULI-program, Technopolis, Veturi Accelerator, Foundation for Finnish Invention (total of some €190k).

The company’s next financing round is planned for H1/2012 and the size of the round will be some €4M.

Modz

19

Contact person: Geir Christian Melen

Location: Oslo, Norway

E-maii: [email protected]

Phone: +47 913 02 965 Web: www.ostomycure.com

OstomyCure is a medical technology company developing an innovative new solution for evacuation of fluids from the intestines.

Ostomycure has developed an implant for stoma patients that could potentially change the lives of hund-reds of thousands people globally. The implant, together with a number of disposable products, forms a system called TIES®. The TIES® system lets patients live stoma bag-free lives, and can thus provide a significant improvement in quality of life for these patients.

The implant has been developed over several years, and has now been tested with encouraging results in an ongoing clinical study where 4 patients have received the implant.

OstomyCure expects to grow significantly over the coming years provided a successful outcome in the ongoing clinical trial.

The market for stoma products is growing and is currently estimated at about 2 billion USD per year.

OstomyCure currently has a burn rate of approximately NOK 1 million per month and represents an opp-ortunity to invest in a med-tech company with a large addressable market, and with a unique, proprietary technology that generates recurring revenue by sale of disposables. The company is focused on esta-blishing multiple exit opportunities for investors, including trade sale and listing..

Ostomycure

20

Relaxbirth Ltd. is looking for investors to participate in this stage of be-ginning market entries in Europe and enhancing our marketing-oriented team for bringing our system to the global market.

The advantages and strengths of the Relaxbirth® System stem from a method based on human ergo-nomics, customer/user orientation and a natural way of giving birth. Hardware, services and know-how are combined into a unique package, currently without equal, or any direct competitors.

The system has been widely presented to opinion leaders and childbirth experts. Also, it has attracted attention in various professional conferences, fairs and exhibitions in Finland and in Sweden. The feed-back has been extremely promising for sales.

Relaxbirth® has been tested in several clinics, including the Helsinki University Maternity Hospital. The Finnish Institute of Occupational Health has also successfully tested the ergonomics and usability of our product. The first trials in Sweden have also begun.

Relaxbirth® increasaes the well-being of the mother, baby and the clinical staff by making the delivery process faster, safer, easier and more comfortable and relaxed. The goal of the Relaxbirth® method is also to increase the number of normal vaginal births and to reduce stress and fears related to child-birth. For the hospital owner/financer, the costs of the clinics will also be reduced and efficiency and competitiveness will be improved. In effect, Relaxbirth is also a new philosophy in childbirth, changing the mother from a helpless object to the master of the situation! This brings satisfied customers to the hospitals adopting Relaxbirth.

Every second, four children are born in the World, in Western Europe alone, there are over 10.000 birthing clinics, preseting a market opportunity of over 1 billion Euros.

Contact person: Jukka-Pekka Luostarinen

Location: Espoo, Finland


Phone: +358 447 15 00 80 Web: www.relaxbirth.com

Relaxbirth

21

Setred is a technology company that has developed a new unique plug and play 3D display. The technology enables high quality 3D without the use of glasses or other head tracking devices. Setred’s ambition is to be-come the world leading supplier of 3D displays.

Recent years have seen a rapid technological development within diagnostic imaging and other medi-cal applications using visual information. Standard medical imaging technologies such as CT, MR and 3D ultrasound all generate 3D volume data sets. Showing these data in 3D can add information to the image, supporting individual interpretation and supporting cross discipline understanding.

The Setred technology has high resolution, large depth and colour replication. It requires no glasses to see 3D and has wide viewing angle allowing several people looking at the same time. It has look around abilities, meaning the user can look around objects on the display by moving her head side-ways. This makes it uniquely suited to users within the medical sector.

Contact person: Jon Riekeles



Phone: :+47 97 62 95 7 Web: http://setred.com/

Setred

22

Contact person: Aslak Felin

Location: Gothenburg, Sweden


Phone: +4670 602 17 45 Web: www.sencere.com

SenCere is moving from their incubator stage to its business development stage with a first product batch, a signed distribution agreement and a first sale. SenCere offers three different products that are used to prevent pres-sure ulcers based on a single technology platform targeted to three niche markets.

The product platform, SitSafe, is a pressure sensor mat that is used under immobile wheelchair patients to warn when unloading from harmful pressure is needed or visualize the pressure distribution. Pressure ulcers can cost more than €100 000 and one year to heal. 10.000 people each year have pressure ulcers in Sweden alone.

The estimated market for SenCeres product family is over € 120 million. The occurrences of pressure ulcers are often associated with neglect and the only measure currently available is to continually relieve the affected areas.

SenCere is looking for an investment of €1 million for a value of €1.5 million to reach break-even in three years, sales through a foreign distributor and a product for the bedridden. SenCeres projects aid equip-ment providers will provide bids for the company after the fifth years when sales hit €5 million. SenCere estimates an exit to an established aid equipment provider. .

Sencere

23

Contact person: Ingemar Fredriksson



Phone: +46 708 46 33 75 Web: www.operatingtheatres.se

Our product is Operating Theatres where the main benefit for the customer is ultra clean air: ISO class 5 (grade B). This is achieved based on re-search that has been carried out by Johan Nordenadler and that gave him his Doctorate at KTH in february 2011.

Clean air in the operating room is essential in order to reduce the level of post operate infections which is huge problem that is expected to escaleta due to increased antibiotics resistance. Post operative infections occur in several percent of all surgery carried out (the percentage varies in different countries and for different types of surger, estimated average is 3-4%). This of cours means lower patient safety and also huge costs for the healt chare sector which is why it has drawn more and more attention from politicians. In Sweden a new law came into force from January 2011 and in USA President Obama has suggested that hospitals should not be paid for readmissions after 2012. Appart from very clean air the solution reduce the energy consumtion which means it also brings cost and environmental benefits.

Manufacturing is done according to pharmaceutical standards in modules that are factory built and as-sembled to turn key units at sight anywhere in the world within approximately six months. The turn key solution and short delivery time is additional benefits for the customer and may for some customers be the main benefit. The producing factory origins from Pharmadule Emtunga who have been working with the modular concept for decades.

One crucial factor for us is time to market since we can offer a unique solution to a problem that has just recently started to be commonly noticed and adressed. Thus we seek new owners who can contribute

Swedish Operating Theathres

24

Contact person: Timo Ahopelto

Location: Oulunsalo, Finland


Phone: +358 400 569 628 Web: http://valkee.com

Valkee bright light headset cures and prevents depression and circadian rhythm sleep disorders by channeling bright light direct-to-brain via ear canal.

Valkee is based on scientific work at University of Oulu since 2007, and revolutionary findings on hu-man brain photosensitivity. In clinical trials, 9 of 10 severely depressed have been cured in 4 weeks with a daily 8-12 minute therapy - a revolutionary result. Currently company studies migraine, jetlag and cognitive performance improvement; launches its product in EU following the successful test-launch in Finland, and prepares the US expansion. Over 80% of the current 6,000 Valkee users recommend the device for their friends

Valkee

25

Volusense

Up to 25% of pre-school children are affected by respiratory illness with a growing incidence rate. Volusense AS has developed, FloRight, a mask-free non-invasive diagnostic and monitoring product for respiratory clinical medicine.

The system is patient and user friendly as there is no mask involved and it is therefore well suited for use in Neonatal Intensive Care Units (NICU) to diagnose and monitor acute and chronic obstructive airway diseases.

Early stage clinical trials at several centers have confirmed the clinical potential of FloRight in the di-agnosis of bronchopulmonary dysplasia as well as in measurement of tidal flow and ventilation moni-toring. Due to its mask-free design, the system also allows monitoring of patients receiving ventilation support and gives valuable decision support during weaning of patients receiving CPAP treatment.

Volusense is ready for partnering with an established industrial player and needs € 1-2 mill to take the system through randomized clinical trials. The exit will be through a merger with an established indu-strial partner.

Contact person: Rianne Vogels



Phone: +479 158 83 39 Web: www.volusense.com

VoluSense

26

Vivoline Medical

Contact person: Peter Sebelius

Location: Lund, Sweden


Phone: +4670 818 68 00 Web: www.vivoline.se

Vivoline LS1 consists of a hardware and a disposable that reconditions, evaluates and preserves lungs that would not have been used otherwise. In a long term perspective, no one should have to die while waiting for a transplantation.

There is a huge need for lungs in the world today. Over 300.000 deaths occur annualy as a result of lung diseases with no known cure. Still, only 3.000 lung transplants are made every year. The limiting factor is availability of organs.

Vivoline has ongoing sales since 2010 and the system has been purchased by clinics performing lung transplants in Sweden and Berlin. Although the product already being CE-marked, a large NHS spon-sored multi-center study is underway in UK using the Vivoline product on five centres on 100 patients.Vivoline expects an annual average growth of 50%, reaching a 800 MSEK turn-over in 2021.

An exit in 2017 should be made possible by showing increased usage of lungs from existing donour groups as well as new; (NHBDs), showing the full potential of 300.000 disposables per year. Potential exit strategies may be acquisition by manufacturers of heart-lung machines or a direct public offering. Vivoline is seeking an investment of 40-60 MSEK.

VivoLine

27

September 8th, Grand Hotel, Stockholm, Sweden Event...

Documents

Transcript of September 8th, Grand Hotel, Stockholm, Sweden Event...